This article is more than 5 years old. Information may no longer be current.

Alimera’s Iluvien receives positive funding recommendation

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The U.K.’s National Institute of Health and Care Excellence has recommended funding for Iluvien as treatment for noninfectious posterior uveitis, Alimera announced.

With this recommendation, the U.K.’s National Health Service will pay for prescriptions for the fluocinolone acetonide intravitreal implant 0.19 mg treatment of noninfectious uveitis affecting the posterior segment, according to the company press release.

Iluvien is also indicated for and funded for the treatment of diabetic macular edema in the U.K.

“We continue to execute on our plans to launch Iluvien’s new indication in Europe for noninfectious posterior uveitis, a significant and, we believe, poorly served medical need. The positive funding recommendation from NICE facilitates patient access in England and Wales for this second indication with funding from the NHS,” said Rick Eiswirth, president and CEO of Alimera Sciences.

The Iluvien sustained release implant is designed to release submicrogram levels of fluocinolone acetonide for 36 months.